01 — At a Glance
The Pharma Factory Where Your Paracetamol Gets Made (Eventually)
- 52-Week High / Low₹575 / ₹312
- Q3 FY26 Revenue₹602.9 Cr
- Q3 FY26 PAT₹40.5 Cr
- Q3 FY26 EPS₹4.44
- Annualised EPS (Q3×4)₹17.76
- Book Value₹161
- Price to Book2.13x
- Dividend Yield0.58%
- Debt / Equity0.39x
- CRISIL RatingAA- / Stable
The Setup: Aarti Drugs makes the active ingredients in your medicines — painkillers, antibiotics, diabetes pills, antiprotozoals — you name the therapy, they’re probably synthesizing it. They ship 50+ APIs to 100+ countries. Yet their Q3 EBITDA margin of 9.3% looks like they’re making paint, not pharmaceuticals. Why? Two greenfield projects (Sayakha amines + Salicylic acid) are tanking utilization, supply chain chaos from China is real, and one “voluntary refurbishment” knocked out capacity. But ask management: “It’s temporary. Growth is coming.” Sure, ji. And your 6–month return is -34.7%. Coincidence?
02 — Introduction
The Boring Ingredient Business That Just Isn’t Boring Anymore
Aarti Drugs. Even the name sounds like what would happen if a PowerPoint presentation became a pharmaceutical company. Zero pizzazz. 100% functional. Exactly what the Indian pharma supply chain ordered.
The company manufactures Active Pharmaceutical Ingredients (APIs) — the chemical compounds that actually do the work inside a medicine. While your local pharma company (Cipla, Lupin, Sun Pharma) slaps a fancy name on a tablet and sells it to you for ₹500, Aarti Drugs is supplying the ₹50 worth of actual chemistry hiding inside. Thankless job. Necessary job. Very, very profitable job — until greenfield capacity ramps and everyone in China decides to price-dump.
Established in 1984 as part of the ₹1,000 crore Aarti Group of Industries, the company operates 9 manufacturing facilities (APIs) + 3 more (Specialty Chemicals), collectively holding 61,053 MTPA (Metric Tonnes Per Annum) of installed capacity across Maharashtra and Gujarat. They’re the world’s largest manufacturers of certain molecules like Fluoroquinolones and Tinidazole. Global exports span 100+ countries. CRISIL rates them AA-/Stable — bank-loan-grade credit quality. And yet, watch the stock chart from the past five years: -14.5% return. Ouch.
Q3 FY26 delivered ₹602.9 crore in revenue (+8% YoY), but EBITDA margin collapsed to 9.3% (vs 11.6% in 9M FY26). Management’s explanation? Greenfield drag. One-time shutdown. China supply chaos. Formulations exports were the hero. Let’s dig into what’s actually happening inside this global pill factory.
Concall Reality (Feb 2026): Management explicitly told investors that the margin dip was “temporary.” They expect 12–13% EBITDA to return first, then target 14–15% steady-state. The Sayakha greenfield (methylamines for metformin APIs) was running at 30% utilization in Q3, targeting 50% by Mar/Apr 2026. Translation: pain is not over yet.
03 — Business Model: WTF Do They Even Do?
Making The Invisible Ingredients That Cure Your Grandma
Members get full access to every article.
